Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients F. Bertucci1,2,3*, P. Finetti1, H. Roche4, J. M. Le Doussal5, L. Marisa6, A. L. Martin7, M. Lacroix-Triki8, C. Blanc-Fournier9, J. Jacquemier10, H. Peyro-Saint-Paul11, P. Viens2,3, C. Sotiriou12, D. Birnbaum1 & F. Penault-Llorca13,14 Department of Molecular Oncology, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm; Institut Paoli-Calmettes (IPC), Marseille; Department of Medical Oncology, IPC, Marseille; Aix-Marseille University, Marseille; Department of Medical Oncology, Institut Claudius Régaud, Toulouse, France; Remora Partners S.A., Lausanne, Suisse; Ligue Nationale Contre le Cancer, Paris; Bureau d’Etudes Cliniques et Thérapeutiques, Unicancer, Paris; Department of Pathology, Institut Claudius Régaud, Toulouse; Department of Pathology, Centre François Baclesse, Rouen; Department of Pathology, IPC, Marseille; Ipsogen S.A., Marseille, France; Breast Cancer Translation Research Laboratory J.C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium; Department of Bio-Pathology, Centre Jean Perrin, Clermont-Ferrand; EA 4677, Auvergne University, Clermont-Ferrand, France

[1]  F. Bertucci,et al.  A refined molecular taxonomy of breast cancer , 2011, Oncogene.

[2]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[3]  Pierre-Marie Martin,et al.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.

[4]  L. Pusztai,et al.  Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.

[5]  F. Bertucci,et al.  Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial , 2011, Breast Cancer Research.

[6]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[7]  C. Sotiriou,et al.  Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis. , 2011, Critical reviews in oncology/hematology.

[8]  F. Bertucci,et al.  Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients , 2011, Breast Cancer Research and Treatment.

[9]  Andrew R. Green,et al.  MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups , 2011, Breast Cancer Research and Treatment.

[10]  F. Bertucci,et al.  Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer , 2011, Breast Cancer Research and Treatment.

[11]  Shu Ichihara,et al.  Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.

[12]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[13]  P. Diest,et al.  Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer , 2010, Breast Cancer Research and Treatment.

[14]  Benjamin Haibe-Kains,et al.  Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues , 2009, BMC Genomics.

[15]  F. Penault-Llorca,et al.  Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Axel Hausen,et al.  Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers , 2009, Breast Cancer Research and Treatment.

[18]  C Caldas,et al.  Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.

[19]  Ian O Ellis,et al.  Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[21]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[22]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[24]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[25]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[27]  T. Delozier,et al.  Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[29]  Christine Desmedt,et al.  Proliferation: the Most Prominent Predictor of Clinical Outcome in Breast Cancer , 2006, Cell cycle.

[30]  P Kronqvist,et al.  Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index , 2006, Histopathology.

[31]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[32]  F. Bertucci,et al.  Gene expression profiling and clinical outcome in breast cancer. , 2006, Omics : a journal of integrative biology.

[33]  Nobuya Sano,et al.  Problems in histological grading of malignancy and its clinical significance in patients with operable Breast Cancer , 2006, Breast cancer.

[34]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. V. van Diest,et al.  Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Vincent-Salomon,et al.  Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. , 2004, Anticancer research.

[37]  J. Baak,et al.  Prognostic value of proliferation in invasive breast cancer: a review , 2004, Journal of Clinical Pathology.

[38]  A. Hanby,et al.  Mitotic counts provide additional prognostic information in grade II mammary carcinoma , 2002, The Journal of pathology.

[39]  M. Daidone,et al.  Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.

[40]  M. J. van de Vijver,et al.  Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial , 2000, Cancer.

[41]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[42]  M. Fernö,et al.  Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. , 1999, Journal of the National Cancer Institute.

[43]  A. Thor,et al.  Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  K Vajda,et al.  [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.

[45]  P. V. van Diest,et al.  Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. , 1995, Human pathology.

[46]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[47]  C. Quinn,et al.  The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables , 1990, The Journal of pathology.

[48]  S Friedman,et al.  Prognostic value of histologic grade nuclear components of Scarff‐Bloom‐Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas , 1989, Cancer.

[49]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.